MA38668A1 - Cristal stabilisé de chlorhydrate de tipiracil, et son procédé de cristallisation - Google Patents
Cristal stabilisé de chlorhydrate de tipiracil, et son procédé de cristallisationInfo
- Publication number
- MA38668A1 MA38668A1 MA38668A MA38668A MA38668A1 MA 38668 A1 MA38668 A1 MA 38668A1 MA 38668 A MA38668 A MA 38668A MA 38668 A MA38668 A MA 38668A MA 38668 A1 MA38668 A1 MA 38668A1
- Authority
- MA
- Morocco
- Prior art keywords
- crystal
- crystallization process
- tipiracil hydrochloride
- stabilized crystal
- stabilized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
La présente invention aborde le problème de production d'un cristal stabilisé de monochlorhydrate de 5-chloro-6-[(2-iminopyrrolidin-1-yl)méthyl]- pyrimidine-2,4(1h,3h)-dione. Comme moyen pour résoudre le problème, il est proposé un cristal de monochlorhydrate de 5-chloro-6-[(2-iminopyrrolidin- 1-yl)méthyl]pyrimidine-2,4(1h,3h)-dione. Le cristal présente des pics caractéristiques à des angles de diffraction (2? ± 0,1°) de 11,6°, 17,2°, 17,8°, 23,3°, 27,1° et 29,3° dans la diffraction des rayons x sur poudre.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013126567 | 2013-06-17 | ||
| PCT/JP2014/065985 WO2014203877A1 (fr) | 2013-06-17 | 2014-06-17 | Cristal stabilisé de chlorhydrate de tipiracil, et son procédé de cristallisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38668A1 true MA38668A1 (fr) | 2018-05-31 |
| MA38668B2 MA38668B2 (fr) | 2019-09-30 |
Family
ID=52104609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38668A MA38668B2 (fr) | 2013-06-17 | 2014-06-17 | Cristal stabilisé de chlorhydrate de tipiracil, et son procédé de cristallisation |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US9527833B2 (fr) |
| EP (2) | EP3012255B1 (fr) |
| JP (2) | JP6364409B2 (fr) |
| KR (1) | KR101806346B1 (fr) |
| CN (4) | CN104395307A (fr) |
| AU (3) | AU2014282281C1 (fr) |
| BR (1) | BR112015031619B1 (fr) |
| CA (2) | CA2985006C (fr) |
| CY (1) | CY1124868T1 (fr) |
| DK (1) | DK3012255T3 (fr) |
| ES (1) | ES2898408T3 (fr) |
| GE (3) | GEP20186875B (fr) |
| HK (1) | HK1203071A1 (fr) |
| HR (1) | HRP20211903T1 (fr) |
| HU (1) | HUE057352T2 (fr) |
| LT (1) | LT3012255T (fr) |
| MA (1) | MA38668B2 (fr) |
| MX (2) | MX2015016986A (fr) |
| MY (2) | MY205261A (fr) |
| NZ (1) | NZ714090A (fr) |
| PH (1) | PH12015502809B1 (fr) |
| PL (1) | PL3012255T3 (fr) |
| PT (1) | PT3012255T (fr) |
| RS (1) | RS62691B1 (fr) |
| RU (2) | RU2674441C1 (fr) |
| SG (4) | SG10201710916YA (fr) |
| SI (1) | SI3012255T1 (fr) |
| SM (1) | SMT202100689T1 (fr) |
| TW (1) | TWI639592B (fr) |
| UA (1) | UA112626C2 (fr) |
| WO (1) | WO2014203877A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015031619B1 (pt) | 2013-06-17 | 2023-01-17 | Taiho Pharmaceutical Co., Ltd | Formas cristalinas i e iii de cloridrato de 5-cloro-6-(2-iminopirrolidin-1-il)metil-2,4(1h,3h)-pirimidinodiona, composição farmacêutica e método de produção |
| CN104744443A (zh) * | 2013-12-26 | 2015-07-01 | 江苏豪森药业股份有限公司 | 嘧啶二酮类化合物盐酸盐新晶型及其制备方法 |
| CN106333952A (zh) * | 2014-02-19 | 2017-01-18 | 齐鲁制药有限公司 | 一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法 |
| CN104945385A (zh) * | 2014-03-31 | 2015-09-30 | 江苏豪森药业股份有限公司 | Tipracil盐酸盐的新晶型及其制备方法 |
| CN106018573B (zh) * | 2016-03-16 | 2018-09-18 | 江苏悦兴药业有限公司 | 一种tas-102中盐酸替比拉西的纯度检测方法 |
| CN105859691A (zh) * | 2016-04-07 | 2016-08-17 | 扬子江药业集团南京海陵药业有限公司 | 一种胸苷磷酸化酶抑制剂的新型结晶形式及其制备方法 |
| WO2018039359A1 (fr) * | 2016-08-23 | 2018-03-01 | Board Of Regents, The University Of Texas System | Procédés de traitement d'une maladie osseuse associée à un cancer. |
| WO2019002407A1 (fr) * | 2017-06-28 | 2019-01-03 | Amneal Pharmaceuticals Company Gmbh | Procédé de préparation de tipiracil chlorhydrate |
| CN107216314A (zh) * | 2017-08-02 | 2017-09-29 | 国药心制药有限公司 | 一种盐酸替匹嘧啶的晶型及其制备方法 |
| WO2019049174A1 (fr) * | 2017-09-07 | 2019-03-14 | Msn Laboratories Private Limited, R&D Center | Formes à l'état solide de chlorhydrate de 5-chloro-6-[(2-iminopyrrolidin-1-yl)méthyl]pyrimidine-2,4-(1h,3h)-dione et procédés de préparation associés |
| US20200283414A1 (en) * | 2017-09-14 | 2020-09-10 | Aurobindo Pharma Ltd | Process for preparing crystalline Tipiracil Hydrochloride |
| JP7330180B2 (ja) * | 2017-11-02 | 2023-08-21 | プロコス ソシエタ ペル アチオニ | チピラシル塩酸塩結晶ｉｉｉ型の製造方法 |
| US11730753B2 (en) | 2018-03-03 | 2023-08-22 | Natco Pharma Limited | Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227726B1 (en) | 1995-03-29 | 2012-01-30 | Taiho Pharmaceutical Co Ltd | Uracyl-derivatives and antitumor effect potentiator and antitumor agent containing the same |
| JP3088758B2 (ja) | 1996-09-24 | 2000-09-18 | 大鵬薬品工業株式会社 | ウラシル誘導体を含有する癌転移抑制剤 |
| JP4049477B2 (ja) | 1999-03-23 | 2008-02-20 | 大鵬薬品工業株式会社 | 副作用軽減剤 |
| JP4110347B2 (ja) | 1999-11-05 | 2008-07-02 | 大鵬薬品工業株式会社 | 抗ｈｉｖ剤 |
| US7799783B2 (en) * | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| ES2382673T3 (es) | 2006-04-13 | 2012-06-12 | Taiho Pharmaceutical Co., Ltd. | Agente terapéutico para la enfermedad inflamatoria intestinal |
| BRPI0713333A2 (pt) | 2006-06-30 | 2012-03-06 | Taiho Pharmaceutical Co., Ltd. | Potencializador de terapia de radiação |
| BR112015031619B1 (pt) | 2013-06-17 | 2023-01-17 | Taiho Pharmaceutical Co., Ltd | Formas cristalinas i e iii de cloridrato de 5-cloro-6-(2-iminopirrolidin-1-il)metil-2,4(1h,3h)-pirimidinodiona, composição farmacêutica e método de produção |
| CN103613877B (zh) * | 2013-11-20 | 2017-09-19 | 上海锦湖日丽塑料有限公司 | 适于吹塑成型的高耐热abs树脂组合物及其制备方法 |
| CN104744443A (zh) | 2013-12-26 | 2015-07-01 | 江苏豪森药业股份有限公司 | 嘧啶二酮类化合物盐酸盐新晶型及其制备方法 |
| CN106333952A (zh) | 2014-02-19 | 2017-01-18 | 齐鲁制药有限公司 | 一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法 |
| CN104945384B (zh) | 2014-03-25 | 2018-10-16 | 江苏豪森药业集团有限公司 | 5-氯-6-[(2-亚氨基-1-吡咯烷)甲基]-2,4(1h,3h)-嘧啶二酮或其盐的制备方法 |
| CN104945385A (zh) | 2014-03-31 | 2015-09-30 | 江苏豪森药业股份有限公司 | Tipracil盐酸盐的新晶型及其制备方法 |
| CN103980253B (zh) | 2014-05-06 | 2015-07-08 | 济南百诺医药科技开发有限公司 | 一种5-氯-6-(2-亚氨基吡咯烷基-1-基)甲基-2,4-(1h, 3h)嘧啶二酮盐酸盐的合成方法 |
-
2014
- 2014-06-17 BR BR112015031619-0A patent/BR112015031619B1/pt active IP Right Grant
- 2014-06-17 WO PCT/JP2014/065985 patent/WO2014203877A1/fr not_active Ceased
- 2014-06-17 CN CN201480000562.4A patent/CN104395307A/zh active Pending
- 2014-06-17 CA CA2985006A patent/CA2985006C/fr active Active
- 2014-06-17 MY MYPI2018001900A patent/MY205261A/en unknown
- 2014-06-17 NZ NZ714090A patent/NZ714090A/en unknown
- 2014-06-17 GE GEAP201414034A patent/GEP20186875B/en unknown
- 2014-06-17 SG SG10201710916YA patent/SG10201710916YA/en unknown
- 2014-06-17 KR KR1020167001279A patent/KR101806346B1/ko active Active
- 2014-06-17 MX MX2015016986A patent/MX2015016986A/es active IP Right Grant
- 2014-06-17 CN CN201910111208.3A patent/CN109912573A/zh active Pending
- 2014-06-17 JP JP2015522923A patent/JP6364409B2/ja active Active
- 2014-06-17 RU RU2017124790A patent/RU2674441C1/ru active
- 2014-06-17 EP EP14814354.8A patent/EP3012255B1/fr active Active
- 2014-06-17 GE GEAP201814034A patent/GEAP201814034A/en unknown
- 2014-06-17 MY MYPI2015002887A patent/MY173410A/en unknown
- 2014-06-17 SG SG10201912293UA patent/SG10201912293UA/en unknown
- 2014-06-17 HK HK15103542.0A patent/HK1203071A1/xx unknown
- 2014-06-17 CN CN201910933531.9A patent/CN110746403A/zh active Pending
- 2014-06-17 LT LTEPPCT/JP2014/065985T patent/LT3012255T/lt unknown
- 2014-06-17 AU AU2014282281A patent/AU2014282281C1/en active Active
- 2014-06-17 US US14/896,748 patent/US9527833B2/en active Active
- 2014-06-17 PL PL14814354T patent/PL3012255T3/pl unknown
- 2014-06-17 TW TW103120948A patent/TWI639592B/zh active
- 2014-06-17 SG SG11201509189SA patent/SG11201509189SA/en unknown
- 2014-06-17 MX MX2018009151A patent/MX383401B/es unknown
- 2014-06-17 UA UAA201600333A patent/UA112626C2/uk unknown
- 2014-06-17 SG SG10202007643SA patent/SG10202007643SA/en unknown
- 2014-06-17 SM SM20210689T patent/SMT202100689T1/it unknown
- 2014-06-17 HU HUE14814354A patent/HUE057352T2/hu unknown
- 2014-06-17 EP EP17204730.0A patent/EP3305779A1/fr active Pending
- 2014-06-17 CN CN201610818347.6A patent/CN106967051A/zh active Pending
- 2014-06-17 MA MA38668A patent/MA38668B2/fr unknown
- 2014-06-17 PT PT148143548T patent/PT3012255T/pt unknown
- 2014-06-17 ES ES14814354T patent/ES2898408T3/es active Active
- 2014-06-17 RS RS20211505A patent/RS62691B1/sr unknown
- 2014-06-17 GE GEAP201414225A patent/GEP20186841B/en unknown
- 2014-06-17 HR HRP20211903TT patent/HRP20211903T1/hr unknown
- 2014-06-17 DK DK14814354.8T patent/DK3012255T3/da active
- 2014-06-17 SI SI201431915T patent/SI3012255T1/sl unknown
- 2014-06-17 RU RU2016100972A patent/RU2640417C2/ru active
- 2014-06-17 CA CA2914999A patent/CA2914999C/fr active Active
-
2015
- 2015-12-17 PH PH12015502809A patent/PH12015502809B1/en unknown
-
2016
- 2016-11-16 US US15/352,858 patent/US10138223B2/en active Active
-
2017
- 2017-07-24 AU AU2017208215A patent/AU2017208215C1/en active Active
-
2018
- 2018-05-02 US US15/969,434 patent/US10457666B2/en active Active
- 2018-07-02 JP JP2018126102A patent/JP6526883B2/ja active Active
- 2018-08-20 AU AU2018219967A patent/AU2018219967C1/en active Active
-
2021
- 2021-12-07 CY CY20211101073T patent/CY1124868T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38668A1 (fr) | Cristal stabilisé de chlorhydrate de tipiracil, et son procédé de cristallisation | |
| PH12021550809A1 (en) | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | |
| MY182403A (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| MX2016006564A (es) | Compuestos dihidropirimidina y su aplicacion en productos farmaceuticos. | |
| MX2013012983A (es) | Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton. | |
| EP2832687A4 (fr) | Procédé de production de poudre de nitrure de silicium, poudre de nitrure de silicium, corps fritté de nitrure de silicium et substrat de circuit l'utilisant | |
| PE20160664A1 (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina | |
| JP2015501783A5 (fr) | ||
| PE20130405A1 (es) | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso | |
| MX2014006026A (es) | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). | |
| PH12014502496B1 (en) | Bicyclically substituted uracils and the use thereof | |
| NZ705578A (en) | Coated pharmaceutical composition containing regorafenib | |
| PE20201495A1 (es) | Compuesto de pirimidina como inhibidor de las janocinasas | |
| EP2802030A4 (fr) | Précurseur pour la préparation d'oxyde de métal de transition au composite au lithium et procédé de préparation | |
| MX358172B (es) | Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson. | |
| EP2846382A4 (fr) | Précurseur pour la préparation d'oxyde de métal de transition composite au lithium et son procédé de préparation | |
| EP2902775A4 (fr) | Électrode de capteur, son procédé de fabrication, et pâte métallique pour formation d'électrode | |
| PE20130218A1 (es) | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado | |
| EP2966148A4 (fr) | Procédé de production d'un luminophore nitruré, poudre de nitrure de silicium pour luminophore nitruré et luminophore nitruré | |
| EP2431330A4 (fr) | Composition pour former un film mince d'oxyde de zinc dopé ou non dopé, et procédé de production d'un film mince d'oxyde de zinc l'utilisant | |
| PH12014502465A1 (en) | Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists | |
| IN2014MN02467A (fr) | ||
| EP2658875A4 (fr) | Procédé de préparation d'amidon hydroxyalkylé | |
| PH12015502692B1 (en) | Ethynyl derivatives as metabotropic glutamate receptor antagonists | |
| EP2884567A4 (fr) | Précurseur de matériau actif d'électrode recouvert de métal, et son procédé de préparation |